Boston Scientific’s cardiovascular division, representing approximately $50 billion in annual revenue, is projected to outpace global market expansion by 200 basis points over the next three years. Key segments include Electrophysiology (EP), WATCHMAN left atrial appendage closure, and interventional cardiology therapies (ICTx). Management forecasts double-digit compound annual growth in EP and high-single-digit gains in ICTx, driven by rising atrial fibrillation procedures and peripheral artery disease interventions. These projections rest on a broad product portfolio that covers mapping systems, ablation catheters, drug-coated balloons and embolic protection devices.

In the most recent fiscal quarter, the EP franchise delivered a 15% year-over-year revenue increase, driven by 30% growth in high-power ablation catheter shipments and greater adoption of the Rhythmia HDx mapping system. Procedural volume climbed 18%, reflecting expanded hospital reimbursement and guideline upgrades recommending earlier intervention for paroxysmal and persistent atrial fibrillation. Boston Scientific added 200 new EP accounts, bringing the total to over 1,100 active centers globally. Operating margin in this segment improved by 120 basis points to 28.5%, reflecting economies of scale and streamlined manufacturing.

WATCHMAN device revenue grew 10% year-on-year, with 1,800 units implanted in the quarter, up from 1,650 a year earlier. Reimbursement approvals in Japan and expansion in Europe drove 25% regional growth. Boston Scientific’s $1.5 billion acquisition of Auryon in late 2025 added a next-generation mapping technology complementing WATCHMAN procedures, expected to boost cross-sell opportunities by 20%. Integration activities are on track, with combined R&D teams targeting launch of an integrated EP-WATCHMAN solution by 2027. Management estimates this combo product could address an incremental addressable market of $4 billion annually.